CLL post-ibrutinib: CAR T-cell therapy shown to result in durable molecular remissions – Lymphoma Hub
Lymphoma Hub |
CLL post-ibrutinib: CAR T-cell therapy shown to result in durable molecular remissions
Lymphoma Hub Use of anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy in CLL previously treated with ibrutinib has recently been shown to induce 'durable molecular remissions' in a phase I/II open-label study. The study, published in the Journal of Clinical … |
